- Conditions
- Glioblastoma Multiforme
- Interventions
- TPI 287, Bevacizumab
- Drug
- Lead sponsor
- Cortice Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Tampa, Florida • Chicago, Illinois + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2857–2880
of 84,083
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Atopic Dermatitis
- Interventions
- Hydrogel vehicle, Eucerin Lotion
- Drug
- Lead sponsor
- Derm Research, PLLC
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Advanced Small Intestine Cancer, Appendiceal Cancers
- Interventions
- Patients will be treated with NALIRIFOX (liposomal irinotecan 50 mg/m2 + 5-FU 2400 mg/m2 + LV 400 mg/m2 + oxaliplatin 60 mg/m2, IV) every 2 weeks for 12 months
- Drug
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Body Fat Disorder
- Interventions
- The Zeltiq CoolSculpting System
- Device
- Lead sponsor
- Zeltiq Aesthetics
- Industry
- Eligibility
- 22 Years to 65 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Pleasanton, California
- Conditions
- Hemophilia A
- Interventions
- Rituximab
- Drug
- Lead sponsor
- Carelon Research
- Other
- Eligibility
- 18 Months and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 13
- States / cities
- Orange, California • Atlanta, Georgia • Chicago, Illinois + 10 more
- Conditions
- Osteoarthritis Thumb
- Interventions
- Trapeziectomy with ligament reconstruction (I; LRTI), Trapeziectomy with suture suspensionplasty (II; SS), Arthroscopic Trapeziectomy (III; AT)
- Procedure
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 165 participants
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Chronic Musculoskeletal Pain, Chronic Shoulder Pain, Chronic Knee Pain
- Interventions
- Laterality Training, Sham (No Treatment)
- Behavioral · Other
- Lead sponsor
- Hawaii Pacific University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 2
- States / cities
- Moline, Illinois • Davenport, Iowa
- Conditions
- Defibrillators, Implantable, Tachycardia, Ventricular
- Interventions
- Ablation, Amiodarone
- Procedure · Drug
- Lead sponsor
- Population Health Research Institute
- Other
- Eligibility
- 19 Years to 84 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Rochester, Minnesota • Philadelphia, Pennsylvania + 2 more
- Conditions
- Executive Dysfunction, Parkinson Disease, Quality of Life
- Interventions
- High-speed yoga multi-directional yoga
- Behavioral
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Coral Gables, Florida
- Conditions
- Herpes Labialis
- Interventions
- Iontophoretic delivery of acyclovir
- Drug
- Lead sponsor
- Transport Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 810 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Santa Rosa, California • Pinellas Park, Florida + 10 more
- Conditions
- Prostatic Neoplasms
- Interventions
- JNJ-101556143
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 7
- States / cities
- Largo, Florida • Chicago Ridge, Illinois • Carmel, Indiana + 4 more
- Conditions
- Frailty
- Interventions
- Prehabilitation
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Small Cell Lung Cancer, Solid Tumor
- Interventions
- APG-1252
- Drug
- Lead sponsor
- Ascentage Pharma Group Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 2
- States / cities
- Grand Rapids, Michigan • San Antonio, Texas
- Conditions
- Metastatic Cancer
- Interventions
- 90Y-NM600
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Sleep Apnea Syndromes
- Interventions
- NightBalance Sleep Position Trainer (SPT), Automated Adjusting Positive Airway Pressure (APAP)
- Device
- Lead sponsor
- NightBalance
- Industry
- Eligibility
- 20 Years to 80 Years
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Gainesville, Florida + 8 more
- Conditions
- Healthy
- Interventions
- Treatment A: 400 mg Pacritinib P3CT, Treatment B: 400 mg of pacritinib FMI
- Drug
- Lead sponsor
- CTI BioPharma
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Evansville, Indiana
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Splenic Marginal Zone Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Small Lymphocytic Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Waldenström Macroglobulinemia
- Interventions
- ispinesib, laboratory biomarker analysis, pharmacological study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Cancer of the Uterine Cervix
- Interventions
- Not listed
- Lead sponsor
- Trans Tasman Radiation Oncology Group
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Substance Use, Substance Abuse, Suicide, Adolescent
- Interventions
- WisePath for Teens, Peer Support Services (PSS), Control
- Other · Behavioral · Device
- Lead sponsor
- Evidence-Based Practice Institute, Seattle, WA
- Industry
- Eligibility
- 13 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Seattle, Washington
- Conditions
- Solid Tumors
- Interventions
- ONT-10
- Biological
- Lead sponsor
- Cascadian Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Non Hodgkin Lymphoma
- Interventions
- UF-KURE19 CAR-T cells, Fludarabine, Cyclophosphamide
- Biological · Drug
- Lead sponsor
- David Wald
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 3
- States / cities
- Iowa City, Iowa • Cleveland, Ohio
- Conditions
- Heart Failure, Congestive
- Interventions
- Furosemide, Torsemide, Bumetanide, sacubitril/valsartan, Hydralazine, Isosorbide Dinitrate
- Drug
- Lead sponsor
- Heart Center Research, LLC
- Network
- Eligibility
- 19 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Huntsville, Alabama
- Conditions
- GLUT1DS1, Epilepsy, Glut1 Deficiency Syndrome 1, Autosomal Recessive, Glucose Metabolism Disorders, Glucose Transport Defect, Glucose Transporter Type 1 Deficiency Syndrome, Glucose Transporter Protein Type 1 Deficiency Syndrome
- Interventions
- Triheptanoin
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 24 Months to 35 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Peripheral T-cell Lymphoma
- Interventions
- brentuximab vedotin, cyclophosphamide, doxorubicin, prednisone
- Drug
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Stanford, California • Aurora, Colorado + 25 more